Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | GABRP | O00591 | 3/20 | 0.56 |
| ▸ | GABRD | O14764 | 3/20 | 0.56 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.56 |
| ▸ | GABRB1 | P18505 | 3/20 | 0.56 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.56 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.56 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.56 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.56 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.56 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.56 |
| ▸ | GABRA4 | P48169 | 3/20 | 0.56 |
| ▸ | GABRE | P78334 | 3/20 | 0.56 |
| ▸ | GABRA6 | Q16445 | 3/20 | 0.56 |
| ▸ | GABRG1 | Q8N1C3 | 3/20 | 0.56 |
| ▸ | GABRG3 | Q99928 | 3/20 | 0.56 |
| ▸ | GABRQ | Q9UN88 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3653761 | 0.85 | GABRP (0.53) | SMN1; SMN2RAB9AGABRPGABRDGABRA1 | |
| SCHEMBL3603220 | 0.85 | GABRP (0.56) | SMN1; SMN2RAB9AGABRPGABRDGABRA1 | |
| SCHEMBL4453924 | 0.83 | GABRP (0.59) | SMN1; SMN2RAB9AGABRPGABRDGABRA1 | |
| SCHEMBL480125 | 0.83 | GABRP (0.55) | SMN1; SMN2RAB9AGABRPGABRDGABRA1 | |
| Hydrochloric Acid SCHEMBL1169512 | 0.81 | GABRP (0.58) | SMN1; SMN2RAB9AGABRPGABRDGABRA1 | |
| SCHEMBL24834805 | 0.81 | GABRP (0.47) | SMN1; SMN2RAB9AGABRPGABRDGABRA1 | |
| SCHEMBL311735 | 0.81 | GABRP (0.47) | SMN1; SMN2RAB9AGABRPGABRDGABRA1 | |
| SCHEMBL7330187 | 0.81 | GABRP (0.47) | SMN1; SMN2RAB9AGABRPGABRDGABRA1 | |
| SCHEMBL28780187 | 0.80 | SMN1; SMN2 (0.51) | SMN1; SMN2RAB9AALDH1A1KDM4EHPGD | |
| SCHEMBL15211304 | 0.80 | KDM4E (0.54) | RAB9AGABRA5ALDH1A1KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114507181-B | Propionic acid compound containing 5-substituted tetrahydroisoquinoline, pharmaceutical composition and application thereof | 中国医学科学院药物研究所 | 2024-03-26 | — | — | CN | disclosed |
| CN-114507181-A | Propionic acid compound containing 5-substituted tetrahydroisoquinoline, pharmaceutical composition and application thereof | 中国医学科学院药物研究所 | 2022-05-17 | — | — | CN | disclosed |
| EP-3730487-A1 | AZETIDINE DERIVATIVES AS FXR (NR1H4) MODULATORS | Gilead Sciences, Inc. (US) | 2020-10-28 | — | — | EP | disclosed |
| US-20120329829-A1 | Dopamine Transporter Inhibitors for Use in Treatment of Movement Disorders and Other CNS Indications | PREXA PHARMACEUTICALS, INC. (US) | 2012-12-27 | — | — | US | disclosed |
| US-8258305-B2 | Dopamine transporter inhibitors for use in treatment of movement disorders and other CNS indications | PREXA PHARMACEUTICALS, INC. (US) | 2012-09-04 | — | — | US | disclosed |
| EP-2338881-A1 | Dopamine transporter inhibitors for use in treatment of movement disorders and other CNS indications | Prexa Pharmaceuticals, Inc. (US) | 2011-06-29 | — | — | EP | disclosed |
| US-20100217727-A1 | Dopamine Transporter Inhibitors for Use in Treatment of Movement Disorders and Other CNS Indications | Prexa Pharmaceuticals, Inc. c/o Advent Healthcare Ventures (US) | 2010-08-26 | — | — | US | disclosed |
| US-20100093706-A1 | MULTIMEDIATOR TRANSPORTER INHIBITORS FOR USE IN TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | PREXA PHARMACEUTICALS, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| CN-101573334-A | Multi-mediator transporter inhibitors for the treatment of central nervous system disorders | PREXA PHARMACEUTICALS INC (US) | 2009-11-04 | — | — | CN | disclosed |
| EP-2069300-A2 | MULTIMEDIATOR TRANSPORTER INHIBITORS FOR USE IN TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | PREXA PHARMACEUTICALS, INC. (US) | 2009-06-17 | — | — | EP | disclosed |
| WO-2008024371-A2 | MULTIMEDIATOR TRANSPORTER INHIBITORS FOR USE IN TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | PREXA PHARMACEUTICALS, INC. (US) | 2008-02-28 | — | — | WO | disclosed |
| EP-1853560-A1 | DOPAMINE TRANSPORTER INHIBITORS FOR USE IN TREATMENT OF MOVEMENT DISORDERS AND OTHER CNS INDICATIONS | Psychenomics, Inc. (US) | 2007-11-14 | — | — | EP | disclosed |
| WO-2006091697-A1 | DOPAMINE TRANSPORTER INHIBITORS FOR USE IN TREATMENT OF MOVEMENT DISORDERS AND OTHER CNS INDICATIONS | PSYCHENOMICS, INC. (US) | 2006-08-31 | — | — | WO | disclosed |
| EP-1412515-A2 | TREATMENT OF CNS DISORDERS USING D-AMINO ACID OXIDASE AND D-ASPARTATE OXIDASE ANTAGONISTS | Genset (FR) | 2004-04-28 | — | — | EP | disclosed |
| US-20030185754-A1 | Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists | GENSET, S.A. (FR) | 2003-10-02 | — | — | US | disclosed |
| US-20030166554-A1 | Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists | GENSET, S.A. (FR) | 2003-09-04 | — | — | US | disclosed |
| WO-2003047558-A2 | TREATMENT OF CNS DISORDERS USING D-AMINO ACID OXIDASE AND D-ASPARTATE OXIDASE INHIBITORS | GENSET S.A. (FR) | 2003-06-12 | — | — | WO | disclosed |
| WO-2002066672-A2 | TREATMENT OF CNS DISORDERS USING D-AMINO ACID OXIDASE AND D-ASPARTATE OXIDASE ANTAGONISTS | GENSET S.A. (FR) | 2002-08-29 | — | — | WO | disclosed |
| EP-0548291-A1 | PYRIDYLTHIO OR PYRIDYLOXY ALKANOIC ACIDS | SMITHKLINE BEECHAM CORPORATION (US) | 1993-06-30 | — | — | EP | disclosed |
| WO-1992005156-A1 | PYRIDYLTHIO OR PYRIDYLOXY ALKANOIC ACIDS | SMITHKLINE BEECHAM CORPORATION (US) | 1992-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120329829-A1 | Dopamine Transporter Inhibitors for Use in Treatment of Movement Disorders and Other CNS Indications | SLC6A3, SLC6A2, SLC18A2 | SMN1; SMN2 318/4885RAB9A 400/4885GABRP 441/4885 |
| US-20030185754-A1 | Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists | DDO, DAO, XDH | SMN1; SMN2 2013/4885RAB9A 2909/4885GABRP 109/4885 |
| US-20100093706-A1 | MULTIMEDIATOR TRANSPORTER INHIBITORS FOR USE IN TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | SLC6A4, SLC18A2, SLC6A2 | SMN1; SMN2 597/4885RAB9A 2817/4885GABRP 364/4885 |
| US-20030166554-A1 | Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists | DDO, DAO, XDH | SMN1; SMN2 2013/4885RAB9A 2909/4885GABRP 109/4885 |
| US-20100217727-A1 | Dopamine Transporter Inhibitors for Use in Treatment of Movement Disorders and Other CNS Indications | SLC6A3, SLC6A2, SLC18A2 | SMN1; SMN2 296/4885RAB9A 645/4885GABRP 336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.